Authors
Loading...
Phase I trial indicates 90Y-anti-CD25 Mab plus TMLI shows promise in older patients with R/R leukemia, highlighting safety and efficacy.
Wong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: